The test uses qPCR to measure the methylation level of three bladder cancer-specific biomarkers in patient urine samples.
According to the researchers, the method could enable higher-throughput analyses while removing some of the subjectivity inherent in pathology practice.
The breath-based biopsy firm is collaborating with Renji Hospital to conduct a clinical trial into the early detection of lung cancer in China.
Sienna's in vitro diagnostic is designed to detect the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer.
MicroMedic's CellDetect assay detects early-stage urothelial bladder cancer in about 20 minutes using a unique plant-based dye.
The firm is preparing to launch a clinical trial for the AdxBladder test in the US early in 2019 and use the results to apply for 510(k) clearance with the FDA.
The deal cover's Sienna's in vitro diagnostic for the detection of the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer.
The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million in EU funding to develop a lung cancer assay.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.